Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with Grade III/IV astrocytoma

Journal of Neuro-Oncology

Volumn 27, Issue 2, 1996, Pages 179-189

  Holladay, Frank P ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Astrocytoma; Glioma; Immunotherapy; Interleukin 2; T lymphocytes; Tumor immunity

Indexed keywords

INTERLEUKIN 2;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; GLIOMA; HUMAN; HUMAN CELL; INFLUENZA; LEUKAPHERESIS; LYMPHOCYTE CLONE; MALE; MONONUCLEAR CELL; NAUSEA; RECURRENT CANCER; RISK ASSESSMENT; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 0030034580     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00177482     Document Type: Article

References (29)

1. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175-182,1989
2. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA: Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 64: 743-749, 1986
3. Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-Demasters B, Bellgrau D: Analysis of interleukin-2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: Allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci USA 87: 9577-9581, 1990
4. McCutcheon IE, Baranco RA, Katz DA, Saris SC: Adoptive immunotherapy of intracerebral metastases in mice. J Neurosurg 72: 102-109,1990
5. Merchant RE, Merchant LH, Cook SHS, McVicar DW, Young HF: Intralesional infusion of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of patients with malignant brain tumor. Neurosurgery 23: 725-732,1988
6. Tzeng J-J, Barth RF, Clendenon NR, Gordon WA: Adoptive immunotherapy of a rat glioma using lymphokine activated killer cells and interleukin 2. Cancer Res 50: 4338-4343,1990
7. Foley EJ: Antigenic properties of MCA-induced sarcomas in mice of the strain of origin. Cancer Res 13: 835-837,1953
8. Prehn RT, Main JM: Immunity of MCA-induced sarcomas. J Natl Cancer Inst 18: 769-778,1967
9. Klein G: Tumor-specific transplantation antigens. Cancer Res 28: 625-635,1968
10. Rosenberg SA, Terry W: Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25: 323-388,1977
11. North RJ: The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 35: 89-155,1984
12. Chang AE, Shu S: Immunotherapy with sensitized lymphocytes. Cancer Invest 10: 357-369,1992
13. Holladay FP, Choudhuri R, Heitz T, Wood GW: Generation of cytotoxic immune responses during the progression of a rat glioma. J Neurosurg 80: 90-96,1994
14. Cheever MA, Greenberg PD, Fefer A: Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin-2. J Immunol 125: 1318-1322,1981
15. Cheever MA, Greenberg PD, Gillis S, Fefer A: Specific adoptive therapy of murine leukemia with cells secondarily sensitized in vitro and expanded in IL-2. Progr Cancer Res Ther 22: 127-133,1982
16. Greenberg PD, Cheever MA, Fefer A: Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1 + 2-lymphocytes. J Exp Med 154: 952-963,1981
17. Chou T, Shu S: Cellular interactions and the role of interleukin-2 in the expression and induction of immunity against a syngeneic murine sarcoma. J Immunol 139: 2103-2109,1987
18. Chou T, Chang A, Shu S: Generation of therapeutic T lymphocytes from tumor bearing mice by in vitro sensitization. Culture requirements and characterization of immunologie specificity. J Immunol 140: 2453-2461,1988
19. Shu S, Chou T, Rosenberg SA: In vitro sensitization and expansion with viable tumor cells and interleukin-2 in the generation of specific therapeutic effector cells. J Immunol 136: 3891-3898,1986
20. Shu S, Chou T, Sakai K: Lymphocytes generated by in vivo and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 143: 740-748,1989
21. Sakai K, Chang AE, Shu S: Effector phenotype and immunologic specificity of T cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity. Cellular Immunol 129: 241-255,1990
22. Eberlein TJ, Rosenstein M, Rosenberg SA: Regression of a syngeneic solid tumor by transfer of lymphoid cells expanded in IL-2. J Exp Med 156: 385-397,1982
23. Rosenstein M, Eberlein TJ, Rosenberg SA: Adoptive immunotherapy of established solid tumors: Role of T lymphoid subpopulations. J Immunol 132: 2117-2122,1984
24. Holladay FP, Wood GW: Generation of cellular immune responses against a glioma-associated antigen(s). J Neuroimmunol 44: 27-32,1993
25. Holladay FP, Heitz T, Chen Y-L, Wood GW: Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 31: 528-533,1992
26. Holladay FP, Heitz T, Wood GW: Cytotoxic T lymphocytes, but not lymphokine activated killer cells, exhibit anti-tumor activity against established intracerebral gliomas. J Neurosurg 77: 757-762,1992
27. Holladay FP, Lopez G, De M, Wood GW: Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurgery 30: 499-505,1992
28. + tumor-infiltrating lymphocytes. J Exp Med 173: 647-658,1991
29. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147: 729-737,1991